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ABSTRACT
Objective: We aimed to assess to what extent men make informed choices in the context of prostate cancer screening and how written material contributes to that process. 
Methods: We developed a leaflet describing prostate cancer screening, and a questionnaire consisting of knowledge, attitude, and intended screening uptake components to assess informed decision-making. The leaflet and questionnaire were pilot-tested among men of the target population, adapted accordingly, and sent to 761 members of an online research panel. We operationalized whether the leaflet was read as spending one minute on the leaflet page and by a self-reported answer of respondents. 
Results: The response rate was 66% (501/761). The group who read the leaflet (n=342) correctly answered a knowledge item significantly more often (10.9 versus 8.8; p<0.001) than those who did not read the leaflet (n=159), and made more informed choices (73% versus 56%; p=0.001). There were no significant differences in attitude and intended screening uptake between both groups. 
Conclusion: Having read the leaflet could be one of the factors associated with increased levels of knowledge and informed decision-making. 
Practical implications: The results of this study showed that increasing knowledge and supporting informed decision-making with written material are feasible in prostate cancer screening.
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Informed decision-making based on a leaflet in the context of prostate cancer screening 
1.	INTRODUCTION
Prostate cancer is the most common cancer and the third cause of cancer mortality among men in Europe (1, 2). Population-based screening might reduce the mortality rate of prostate cancer; however, the harm-benefit ratio of such a screening program is being debated  ADDIN EN.CITE (3, 4, 5). The European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown that screening based on Prostate-Specific Antigen (PSA) can reduce the mortality rate of prostate cancer by 20% to 30%; nonetheless, concerns about overdiagnosis and overtreatment were expressed as well  ADDIN EN.CITE (6). Elaborating on the results of the ERSPC study, a simulation study showed that implementing prostate cancer screening may be effective and cost-efficient – with minimal overdiagnosis and overtreatment – when it is limited to two or three screenings among men between the ages of 55 and 59  ADDIN EN.CITE (7). 
Despite these promising results, population-based screening for prostate cancer has not been introduced yet  ADDIN EN.CITE (7). Also in the Netherlands, where over 10,000 men are diagnosed with prostate cancer and 2.500 men die of this disease annually, no prostate cancer screening program has been introduced (8). Dutch general practitioners have a guideline stating that they should not offer a PSA test to men when they do not ask for it. However, when men do ask, a PSA test can be offered on the basis of shared decision-making. If a pilot prostate cancer screening program is implemented at any point to investigate whether a nationwide screening program in the Netherlands would be effective and cost-efficient, all invited men need to be well informed and able to make an informed choice about their participation in this program (9, 10). An informed choice is defined in this paper as a choice which is based on relevant, high-quality knowledge and which represents the values of the decision-maker (11). In this paper, the term is synonymous with informed decision-making. We consider relevant, high-quality knowledge as knowledge which is based on guidelines of the Dutch National Institute for Public Health and the Environment (12). Unlike shared decision-making where clinicians and people make choices together (13), decision-making in the context of screening is mainly based on written information as a result of which the person him- or herself makes a decision about participation. Consequently, the aim of this study is to assess to what extent men make informed choices in the context of prostate cancer screening and how written information contributes to that process.
2.	METHODS
2.1 Questionnaire study
2.1.1. Development of leaflet and questionnaire
We developed a leaflet about prostate cancer screening based on a study about the information quality of PSA screening programs, literature about the communication of medical information, and leaflets of already existing screening programs  ADDIN EN.CITE (8, 14-21). This leaflet was developed for a potential pilot of a population-based prostate cancer screening program in the Netherlands. The resulting draft leaflet was extensively discussed and reviewed by the authors until consensus was reached. This leaflet contained general information on prostate cancer, the pilot research project, the PSA test and possible results, the procedures for biopsy and MRI, and possible treatment options. In addition, an overview of harms and benefits of prostate cancer screening was presented (see Appendix 1 for an English version of the Dutch leaflet text). The topics are based on the guidelines of the Dutch National Institute for Public Health and the Environment (12). These guidelines state 15 topics of screening that have to be mentioned in the information provided for a population-based screening program.
Additionally, we developed a questionnaire to assess the level of informed choice based on similar studies about informed decision-making  ADDIN EN.CITE (11, 22-28). The questionnaire consisted of the following components: knowledge, attitude, intended screening uptake, and familiarity with the PSA test. To further optimize the leaflet and questionnaire, we pilot-tested them in structured face-to-face and phone interviews with six men in the age range of 53 to 57. Questions on the readability, completeness, clarity, and layout of the leaflet and the questionnaire were asked.
2.2. Data collection
The revised versions of the leaflet and the questionnaire were sent to members of the Flycatcher panel. This panel consists of people from the Dutch general public who volunteer to participate in online questionnaire surveys. Male members of this panel in the age range of 45 up to and including 65 years with sufficient understanding of the Dutch language and with no medical history of prostate cancer were asked to read the leaflet and fill out the questionnaire. The respondents had access to the leaflet and questionnaire via the website of Flycatcher. The time that respondents spent on the page of the leaflet was measured and demographic details of these respondents were additionally collected. 
As population-based screening for prostate cancer has not currently been introduced in the Netherlands, we had to test in a hypothetical situation. To make this hypothetical situation as realistic as possible, the survey asked our respondents to pretend that this leaflet was attached to a real invitation for participation in the Dutch prostate cancer screening program. 
2.3 Outcome measures of the questionnaire 
2.3.1. Knowledge
Decision-relevant knowledge was measured using 13 multiple-choice items (Table 2). The 13 multiple-choice items covered decision-relevant knowledge of prostate cancer screening, and were determined on the basis of previously used screening-related knowledge items with regard to colorectal cancer screening, breast cancer screening, and cervical cancer screening. These items were extensively discussed by the authors and piloted in interviews with six men in the target age of prostate cancer screening (29, 30, 31). The items addressed the purpose of the prostate cancer screening program, the prevalence of prostate cancer, the symptoms and development of prostate cancer, the benefits and harms of the screening program, the uncertainty of a PSA test, the treatment options after diagnosis, and the voluntary nature of participation. Response options to these items were “True”, “False” and “I don’t know.” Each correct answer added one point to the knowledge score. As a result, the range of the total knowledge score was 0 to 13. Because there is still no psychometric evaluation of the knowledge element, following earlier research  ADDIN EN.CITE (23, 24, 26), the midpoint of the knowledge scale was used as the threshold for “sufficient knowledge”; a score of eight or higher was categorized as “sufficient knowledge” and a score of seven or lower was categorized as “insufficient knowledge.” 
2.3.2. Attitudes
Respondents’ attitudes toward participation in the screening program were assessed using five items based on similar studies  ADDIN EN.CITE (11, 22, 24, 28). Each item started with the following sentence: “In my opinion, participation in the prostate cancer screening program within 3 months for myself is…” Items were anchored by unimportant/important, frightening/reassuring, not self-evident/self-evident, uncomfortable/not uncomfortable, or harmful/not harmful, each scored on a 7-point Likert scale. The Cronbach’s alpha of the attitude scale of 0.81 indicated good internal consistency.
All answers were summed up and subtracted by 5 (the lowest score that the participant could have). This figure was divided by 30 (the highest score possible minus the lowest score possible) and multiplied by 100, which resulted in a score ranging from 0 to 100. Following the reasoning that the midpoint of the scale represents a neutral attitude (28), a score between 44 and 56 was categorized as “neutral.” A score of 44 or lower was categorized as a “negative attitude toward participation in the prostate cancer screening program” and a score of 56 or higher was categorized as a “positive attitude toward participation in the prostate cancer screening program.” 
2.3.3. Intended screening uptake
Intended screening uptake was assessed by the question: “Imagine that you will receive an invitation within three months to participate in a prostate cancer screening program. Will you participate?” The answer was given on a 7-point Likert scale, anchored by 1 “definitely not” and 7 “definitely.” An answer of 1, 2, or 3 was categorized as “unlikely to participate”; 4 was categorized as “undecided”; and 5, 6, or 7 were categorized as “likely to participate.” 
2.3.4. Informed choice
To assess the level of informed choice, we combined the scores of the knowledge, attitude, and intended screening uptake components (11). A respondent was considered to have made an informed choice when they: 1) had sufficient knowledge, had a positive attitude, and were likely to participate in the screening program; 2) had sufficient knowledge, had a negative attitude, and were unlikely to participate; 3) had sufficient knowledge, had a neutral attitude, and were undecided about participation. All other combinations were categorized as uninformed choices. Because there is no population-based prostate cancer screening program in place yet, we could not follow men over time to see whether they did or did not participate in such a screening program. 
2.4. Statistical analyses
We operationalized whether the leaflet was read as follows: we measured with a time-tracking device how long respondents spent on the leaflet page and we asked the question “did you read the leaflet?” If respondents answered “yes” to the question “did you read the leaflet?” and spent one minute or more on reading the leaflet, they were categorized as having read the leaflet. If respondents answered “no” to the question “did you read the leaflet?” or spent less than one minute on reading the leaflet, they were categorized as not having read the leaflet.
Chi-square tests were used to compare the respondents who read the leaflet and the respondents who did not read the leaflet on categorical variables; t-tests were used for continuous variables. All reported p-values are corrected for educational level and are two-sided, with p<0.05 considered as significant. Analyses were carried out using SPSS version 24 for Windows. 
The Medical Research Ethics Committee of Erasmus University Medical Center approved the study protocol of MEC-2017-1074. 
3.	RESULTS
3.1. Response and descriptive characteristics 
In total, 761 men were sent a questionnaire; 557 of them filled in the questionnaire. However, data from 56 of these 557 respondents were excluded from our analyses because their answers were quite incomplete. As a result, the response rate is 66% (501/761). The mean age of our respondents was 56, while 96% of the respondents were born in the Netherlands (Table 1). Most of the respondents lived together with a partner and children; 16% had a low educational level, 36% an intermediate educational level, and 47% a high educational level. The group who read the leaflet had a significant higher level of education than the group who did not read the leaflet (p<0.001). Overall, the mean time that respondents used to read the leaflet was four minutes and 86% of all respondents reported that the leaflet was clear. Thirty-four percent of the respondents had considered having a PSA test before they filled in the questionnaire and 20% of all respondents had already had a PSA test. 
3.2.	Knowledge 
Of all respondents, 86% had sufficient knowledge and 10 knowledge items were answered correctly on average (Table 2). The three items answered correctly the most often concerned the chance of mortality when prostate cancer is found at an early stage, the aim of the screening program, and the presence of prostate cancer while symptoms are absent. These items were answered correctly by 97%, 96%, and 96% of the respondents who read the leaflet, and by 95%, 95%, and 85% of the respondents who did not read the leaflet respectively. The three items answered the least correctly regarded the need for treatment when prostate cancer is found, a false-negative test result, and complaints when urinating. These items were answered correctly by 63%, 66%, and 67% of the respondents who read the leaflet, and by 31%, 56%, and 37% of the respondents who did not read the leaflet respectively. There was a significant difference in the level of sufficient knowledge between the groups who did and did not read the leaflet. Ninety-six percent of the group who did read the leaflet had sufficient knowledge, whereas 67% of the group who did not read the leaflet had sufficient knowledge (p<0.001).
3.3.	Attitude
Overall, 67% of the respondents had a positive attitude about participation in the prostate cancer screening program, 15% had a neutral attitude, and 18% had a negative attitude about participation in the prostate cancer screening program (Table 3). There was no significant difference between the group who read the leaflet and the group who did not read the leaflet. 
3.4.	Intended screening uptake
The majority of the respondents (77%) indicated that they were likely to participate in the prostate cancer screening program, 13% indicated that they were unlikely to participate, and 10% indicated that they were undecided about their participation (Table 3). Of the group who read the leaflet, 79% were likely to participate in the screening program. This figure was 74% in the group who had not read the leaflet. There was no significant difference between the groups who did and did not read the leaflet. 
3.5.	Informed choice
In this hypothetical situation, 68% of all respondents made an informed choice (Table 4). This percentage was significantly higher in the group who read the leaflet (p=0.001). Seventy-three percent of the respondents who read the leaflet made an informed choice; furthermore, 62% of all respondents who read the leaflet had a positive attitude and indicated that they were likely to participate in the screening program. By contrast, 56% of the respondents who did not read the leaflet made an informed choice, while 44% of all respondents who did not read the leaflet had a positive attitude and indicated that they were likely to participate in the prostate cancer screening program. In total, 24% of the respondents who read the leaflet made an uninformed choice due to conflicting attitudes and intentions. This figure was 21% among respondents who did not read the leaflet. Three percent of the respondents who did read the leaflet made an uninformed choice due to insufficient knowledge, in contrast to 23% of the respondents who did not read the leaflet. Of all men who reported to have had a PSA test before, 83% made an informed choice.
4.	DISCUSSION AND CONCLUSION
4.1. Discussion
The group who read the leaflet reported significantly better knowledge levels than the group who did not read the leaflet, and hence made more informed choices. Seventy-three percent of the respondents who read the leaflet about prostate cancer screening made an informed decision. In a similar study about informed decision-making in the context of breast cancer screening, 88% of the respondents made an informed decision (24). However, breast cancer screening was introduced in the Netherlands in 1990 and we expect the breast cancer screening program to be better known. Based on our study results, we have now adapted the leaflet about prostate cancer screening with regard to the explanation of false-negative test results, urinary tract problems, and treatment options. We consequently expect it to result in informed decision rates of above 73%. 
These knowledge gaps are related to knowledge of complaints when urinating or treatment of prostate cancer. Only 58% of all respondents knew that more frequent urination or a weak stream are often not being caused by prostate cancer and 53% of all respondents knew that treatment is not always needed when prostate cancer is found (see Table 2). So far, population-based prostate cancer screening programs have not been introduced in the Netherlands, nor elsewhere. As a result, we cannot assume our respondents to know all about this topic, even more so since screening is a complicated topic. Interestingly, 82% of the respondents who read the leaflet knew that a high PSA value does not mean that a person certainly has prostate cancer. Conversely, only 66% of this same group knew that a low PSA value in the blood does not mean that a person certainly has no prostate cancer. The fact that false-positive results are easier to understand than false-negative results was also found in other studies  ADDIN EN.CITE (24, 32). It is of importance that not only a false-positive result is understood but also a false-negative result. Insufficient knowledge of a false-negative result may cause a delay in seeking treatment if symptoms appear, for example (33). This delay may subsequently affect survival. To improve the understanding of a false-negative result, a short statement can be added to the written information in order to explain that a normal test result means a low risk of developing cancer (34). For this reason, we recommend reviewing and improving the information provided in the leaflet about false-negative results, so that the concept of false-negative results and false-positive results are both understood. 
A literature review determining the contribution of written material to informed decision-making in the context of screening has shown that no differences in attitude or intended screening uptake between the group who read and the group who did not read the leaflet were found in the majority of the studies in this literature review (35). Also in our study, we found no significant difference in intended screening uptake and attitude between the group who read and the group who did not read the leaflet. This fact may have two explanations. Firstly, the time at which the questionnaire about intended screening uptake and attitude has been filled out may influence the results. We asked the respondents directly after reading the leaflet what their attitude and intended screening uptake were. The time between reading the leaflet and filling out the questionnaire may have given the respondents no opportunity to think about all information provided on the screening program. If the leaflet induced a shift in attitude and intended screening uptake, this shift may consequently have been less likely to be detected. Secondly, a respondent may have a positive or negative attitude toward all screening programs, as a result of which the disease being screened for presumably has limited impact on the attitude and intended screening uptake. In a sample of 500 adults in the United States, 87% believed that routine cancer screening is almost always a good idea, while between 32% and 41% believed that an 80-year-old was irresponsible when they chose not to be tested (36). Also, a study among 2,368 individuals in Switzerland showed that most respondents had a positive attitude in general toward cancer screening and that these attitudes were strongly related to their screening practice (37). Reading the leaflet may therefore have minimal impact on attitude or intended screening uptake.
One strength of this study is that we carefully prepared the leaflet with the input of the target group. We observed that the leaflet presumably contributed to the knowledge levels of respondents, also on sensitive topics such as false-positive PSA test results, without influencing attitude and intended screening uptake. As a result, a possibly useful information source for prostate cancer screening is now available.
Another strength is the large sample size (n=501) of respondents in a comparable age category of the target population of a potential future screening program for prostate cancer. Consequently, the level of informed choices among respondents in this study is presumably comparable to the level of informed choices among possible participants of a potential future screening program for prostate cancer.
Some limitations of this study need to be addressed. First of all, respondents only filled out the questionnaire once. As a result, we do not know what the knowledge, attitude, and intended screening uptake of the respondents were before they read the leaflet or what the influence of the leaflet was on these components. However, as the results of this study showed, some significant differences were found in knowledge and informed choice levels between the respondents who read the leaflet and the respondents who did not read the leaflet. Previous studies about the influence of written information on informed decision-making showed these results as well (35). Consequently, our leaflet presumably induced these differences. 
Furthermore, misclassification of respondents having or not having read the leaflet could have occurred. To minimize misclassification, we used a time-tracking device and added a question to the questionnaire asking whether respondents read the leaflet. A cut-off time of one minute was chosen, because some respondents whose reading time was just above one minute answered “yes” to the question “did you read the leaflet” and provided detailed information in some open questions. However, respondents might have incorrectly answered this question, opened the leaflet without reading it, or saved the leaflet on their computer and read it without being registered by the time-tracking device. As a result, there is a possibility that respondents were included in the wrong group. Nonetheless, when only looking at the classification based on “did you read the leaflet” without taking the reading time of one minute into consideration, 90% of the respondents who self-reported to have read the leaflet had sufficient knowledge and 70% of them made an informed choice. Fifty-one percent of the respondents who self-reported to not have read the leaflet had sufficient knowledge and 45% of them made an informed choice. Consequently, it is unlikely that men who spent very little time on reading the leaflet did so because they were already well informed. However, since about 30% of the men did not read the leaflet, other ways of informing high-risk and other categories of men might be thought of in the future. A limitation of the leaflet is that participants were potentially unable to understand it. Although special attention was paid to the readability by using short sentences and clear headings, for example, 33% of the respondents who did not read the leaflet for longer than one minute indicated that they considered the leaflet unclear.
Additionally, it is known that people with higher educational levels are more likely to participate in surveys (38). The percentage of men between 45 and 65 years old who are highly educated is about 30% in the Netherlands (39). In our study, the percentage of highly educated men was 47% and in the group of men who read the leaflet even 53%. Because men with a high educational level are overrepresented in our study, the results of our study may not apply to the general Dutch population.
	4.2. Conclusion 
To conclude, reading the leaflet might be one of the factors for increased knowledge levels and informed choices. We recommend paying specific attention to false-negative test results, the need for treatment, and specific complaints when providing information, because these aspects were not yet well understood by respondents.
	4.3. Practical implications
The results of this study showed that the leaflet might be one of the factors to support informed decision-making without influencing intended screening uptake and attitude toward the program. It may be feasible to increase decision-relevant knowledge and decrease knowledge gaps with written material. 



APPENDIX 1 - LEAFLET
Prostate cancer
Pilot population screening program
Who should read this leaflet?
This leaflet is intended for men in the age group of 55 to 60 years who are eligible to participate in a pilot population screening program for prostate cancer, and for their relatives.
Note: This leaflet describes a scientific study on prostate cancer that is carried out by the Erasmus Medical Center. This pilot population screening program takes place in the regions of North Holland, Utrecht and Flevoland.
Why a pilot population screening program?
Research in Europe has shown that mortality due to prostate cancer can be reduced by means of population screening programs. To determine whether a population-based screening program for prostate cancer is useful in the Netherlands, we first have to know how many men will participate and how many cases of prostate cancer can be detected. To answer these questions, this pilot population screening program has been set up.
Prostate cancer in the Netherlands
Each year more than 10,000 men in the Netherlands are diagnosed with prostate cancer and 2,500 men die from prostate cancer.
Prostate cancer is the most common type of cancer among men in the Netherlands.
With a population screening program, prostate cancer can be detected early, even before the onset of symptoms. By treating prostate cancer at an early stage, more men can be cured.
If the pilot population screening program has good results, a national population screening program may be introduced. Based on the results of a European study, it is predicted that each year approximately 250 fewer men will die in the Netherlands when a national population screening for prostate cancer is introduced.
 
In absence of a population-based screening program, 25 of each 100 men diagnosed with prostate cancer will die of prostate cancer. If a population-based screening program is introduced, 22 out of each 100 men diagnosed with prostate cancer will die; an estimated 3 fewer men will die of the consequences of this disease.
What is prostate cancer?
The prostate is a gland that is located under the bladder. This gland makes prostatic fluid that carries the sperm cells. When cells in the prostate begin to grow unrestrained, prostate cancer develops.
 
Prostate cancer is especially common in men in the ages between 55 and 85 years. It is rarely diagnosed in men younger than 50 years.
In most cases, prostate cancer grows slowly and because of this it causes little or no symptoms in the beginning.
When prostate cancer spreads to other sites and organs in the body it can cause symptoms, for example, pain in the back. Problems when urinating, such as having to urinate frequently or a limp when urinating, are usually caused by a different prostate disease than cancer, such as a benign enlargement of the prostate. We recommend to visit a doctor in all cases with symptoms such as back pain and problems when urinating.
How will the pilot population screening for prostate cancer be performed?
Participants in this pilot population screening visit a laboratory. A blood sample is taken to determine the PSA value in their blood.
PSA means Prostate Specific Antigen. PSA is a protein that is only made in the prostate.
Depending on this PSA value, we provide advice on follow-up research.
What are possible results?
Low PSA value: PSA value of 1 ng/ml or lower
The probability that prostate cancer will develop in a person in the next 4 to 8 years is very small. That is why a PSA test is no longer necessary in the coming 4 to 8 years. When symptoms arise during this period, we recommend to always visit a doctor.
Average PSA value: PSA value between 1 ng/ml and 3 ng/ml
There is no reason to immediately perform a follow-up assessment. To check whether this PSA value remains the same, we advise the participant to have the PSA test repeated by the general practitioner within 2 years. When symptoms arise in the meantime, we advise to always visit a doctor.
Increased PSA value: PSA value of 3 ng/ml or higher
To find the cause of the increased PSA value, men are referred to a specialist in the hospital for further research.
An increased PSA value can, next to prostate cancer, also be caused by an infection or a benign prostate enlargement.
The specialist in the hospital will determine the risk on prostate cancer by measuring the volume of the prostate and using the Prostate Risk Calculator:
	Measuring the volume of the prostate
The specialist feels with his finger to estimate the volume of the prostate. This is a brief test, but can be experienced as uncomfortable.
	The Prostate Risk Calculator
The Prostate Risk Calculator is a calculation tool enabling the specialist to predict the risk of prostate cancer based on the PSA value in the blood, age, family history and urinary problems.
Depending on the result of the volume measurement and the Prostate Risk Calculator, the specialist provides a recommendation. The following recommendations are possible:
	The specialist can advise to take a blood sample every two years to monitor the PSA value.
	The specialist can advise to perform a biopsy. A biopsy is an invasive procedure in which several small pieces of tissue are taken from the prostate and examined.
	The specialist can advise to perform an MRI scan. Depending on the outcome of the MRI scan, the specialist can advise to carry out a biopsy for further research.
Treatment of prostate cancer
When follow-up research shows that prostate cancer is present, the specialist explains which treatments are possible. The most common treatments for prostate cancer are:
	Radiation (also called radiotherapy)
	Surgery: the prostate will be removed through a surgical procedure
	Hormone therapy: using medicines, the production of certain hormones is inhibited 

More and more often the choice is made to not treat prostate cancer immediately, but to carefully watch the tumor. This is called “Active Surveillance”. For some tumor types it has been shown, treatment may cause adverse effects while treatment is not immediately necessary.
Advantages and disadvantages of the pilot population screening program
The following advantages and disadvantages of the pilot population screening program can help to make a choice about participating in this.
An advantage of this pilot population screening program is that prostate cancer can be detected even before the onset of symptoms. This reduces the probability that the cancer has already spread. If prostate cancer has not yet spread, a treatment is more often successful.
Early detection of prostate cancer can reduce mortality from prostate cancer.
Also a low PSA value in the blood can be reassuring. The absence of prostate cancer can be confirmed in many cases.
But the PSA test does not offer complete certainty. It is possible that the test results in a low PSA value, while prostate cancer is present.
Another disadvantage of the pilot population screening is that a (high) PSA value can be stressful. During follow-up assessments it is not immediately clear whether prostate cancer is present.
There is also a chance of over-treatment. Approximately 2 per 100 men who participate in the pilot population screening program would never have been diagnosed with prostate cancer without this pilot population screening program. Treatment would not have been necessary.

Benefits	Harms
Early detection of prostate cancer	Incomplete certainty of PSA test
Less probability of metastasis	Stress after an unfavorable result
Higher probability of cure and a reduction of prostate cancer mortality	Detection and treatment of cancers that would never have been detected without screening
Reassurance	

Costs
The blood collection in the laboratory to determine the PSA value in the blood is free of costs. The costs of follow-up assessment are covered by the health insurance. It may be that some participants have to pay the costs of a follow-up assessment or a part of it themselves. This depends on how high the deductible is and how much of it has already been used. If you have any questions about this, please contact your health insurer.
Participation in the pilot population screening
Participation in this pilot population screening program is entirely voluntary. Each participant has the right to terminate his participation in this research project at any time. This termination has no financial consequences or consequences for care provision in the future.
Participants in this pilot population screening program will receive the results of the blood collection by mail.
Where to go with questions, comments or complaints?
If you have questions, comments or complaints, you can contact the research team, an independent doctor and a complaints committee.
Contact information Erasmus MC




Table 1, Descriptive characteristics of the study sample and outcome measures
Characteristic 	All respondents  n=501	Respondents who read the leaflet n=342*	Respondents who did not read the leaflet  n=159**	p-value
Age, mean (SD)	56	(5.6)	56	(5.5)	57	(5.8)	0.30
Educational level, Number (%)LowIntermediateHigh 	82    181  238  	(16)(36)(47)	36126180	(11)(37)(53)	465558	(29)(35)(37)	<0.001
Country of birth, Number (%)NetherlandsOther 	482 29   	(96)(4)	33111	(97)(3)	1518	(95)(5)	0.53
Living situation, Number (%)With parent(s)/caretaker(s)AloneTogether with a partner, without childrenTogether with a partner, with childrenWithout a partner, with children	2 9617221318	(0.4)(19)(34)(43)(4)	27111114414	(1)(21)(32)(42)(4)	02561694	(0)(16)(38)(43)(3)	0.37
Time spent reading the leaflet in minutes, mean (SD)	4.1	(7)	5.9	(8)	0.3	(0.3)	NA
Self-reported answer ‘yes' to the question: ‘Did you read the leaflet?’ Number (%)	452	(90)	342	(100)	110	(69)	NA
Reported that the leaflet was clear, Number (%)	429	(86)	323	(94)	106	(67)	0.43
Thought about doing a PSA-test, Number (%)	170	(34)	118	(35)	52	(33)	0.66
Did do a PSA-test before, Number (%)	101	(20)	75	(22)	26	(16)	0.15
*=Respondents answered 'yes' to the question: 'did you read the leaflet?' and spent 1 minute or more on reading the leaflet. 
**=Respondents answered ‘no' to the question: 'did you read the leaflet? or spent less than 1 minute on reading the leaflet.
Percentages may not add to 100 because of rounding



Table 2, Overview of knowledge items
Knowledge item (right answer: correct/incorrect)No. correct answers (%)	All respondents  n=501	Respondents who read the leaflet n=342*	Respondents who did not read the leaflet n=159**	 p-value ***
The aim of the screening program is to detect prostate cancer as early as possible. (correct)	479	(96)	328	(96)	151	(95)	0.41
Prostate cancer is the most common cancer among men in the Netherlands.(correct)	426	(85)	308	(90)	118	(74)	<0.001
The chance of having prostate cancer declines with aging. (incorrect)	449	(90)	309	(90)	140	(88)	0.72
I can have prostate cancer even if I don’t have any symptoms. (correct)	463	(92)	328	(96)	135	(85)	0.001
Complaints when urinating, such as more frequent urination or a weak stream, are often caused by prostate cancer. (incorrect)	288	(58)	229	(67)	59	(37)	<0.001
I certainly have prostate cancer if the blood sample shows that I have a high PSA-value. (incorrect)	374	(75)	280	(82)	94	(59)	<0.001
I certainly do not have prostate cancer if the blood sample shows that I have a low PSA-value. (incorrect)	314	(63)	225	(66)	89	(56)	0.16
The chance of dying is lower when prostate cancer is discovered early. (correct)	484	(97)	333	(97)	151	(95)	0.52
A PSA-test always discovers prostate cancer. (incorrect)	335	(67)	253	(74)	82	(52)	<0.001
When prostate cancer is found, treatment is always needed. (incorrect)	263	(53)	214	(63)	49	(31)	<0.001
Because of this screening program, certain cases of prostate cancer can be found that otherwise never caused any problems. (correct)	402	(80)	290	(85)	112	(70)	0.002
I always get radiotherapy as treatment when further research shows that I have prostate cancer. (incorrect)	397	(79)	302	(88)	95	(60)	<0.001
I can stop at any moment with my participation in the screening program. (correct)	442	(88)	321	(94)	121	(76)	<0.001
Total of correct answers Mean, (SD)	10.2	(2.4)	10.9	(1.8)	8.8	(2.8)	<0.001
Knowledge is categorized as sufficient if respondent correctly answered 8 out of 13 knowledge items correctly:No. of respondents (%)	All respondents  n=501	Respondents who read the leaflet n=342*	Respondents who did not read the leaflet n=159**	p-value***
Sufficient knowledgeInsufficient knowledge 	43368	(86)(13)	32715	(96)(4)	10653	(67)(33)	<0.001
*=Respondents answered 'yes' to the question: 'did you read the leaflet?' and spent 1 minute or more on reading the leaflet. 
**=Respondents answered ‘no’ to the question: 'did you read the leaflet? or spent less than 1 minute on reading the leaflet.
*** = P-value is corrected for educational level.
Percentages may not add to 100 because of rounding








Table 3, Overview of attitude and intended screening uptake
	All respondents  n=501	Respondents who read the leaflet n=342*	Respondents who did not read the leaflet n=159**	p-value***
Attitude scoreNo. of respondents, (%)Negative attitudeNeutral attitudePositive attitude	8975337	(18)(15)(67)	5851233	(17)(15)(68)	3124104	(20)(15)(65)	0.47
Intended screening uptakeNo. of respondents, (%)	Unlikely to participate	Undecided	Likely to participate	6549387	(13)(10)(77)	4032270	(12)(9)(79)	2517117	(16)(11)(74)	0.14
*=Respondents answered 'yes' to the question: 'did you read the leaflet?' and spent 1 minute or more on reading the leaflet. 
**=Respondents answered ‘no' to the question: 'did you read the leaflet? or spent less than 1 minute on reading the leaflet.
*** = P-value is corrected for educational level.
Percentages may not add to 100 because of rounding



Informed choiceNo. of respondents, (%)	All respondents  n=501	Respondents who read the leaflet n=342*	Respondents who did not read the leaflet  n=159**	p-value***
Informed choice:Negative attitude and unlikely to participateNeutral attitude and undecided about participationPositive attitude and likely to participateTotal of informed choicesUninformed choice due to conflicting attitude and intention:Negative attitude and likely to participateNegative attitude and undecided about participationPositive attitude and unlikely to participatePositive attitude and undecided about participationNeutral attitude and likely to participateNeutral attitude and unlikely to participateUninformed choice due to insufficient knowledge:Negative attitude and unlikely to participateNeutral attitude and undecided about participationPositive attitude and likely to participate	338401728116311627145154312478336	(68)(8)(3)(56)(33)(23)(5)(3)(1)(3)(9)(2)(9)(2)(1)(7)	2492711211938319931233710307	(73)(8)(3)(62)(27)(24)(6)(3)(1)(4)(10)(2)(3)(1)(0)(2)	891367070338523105375329	(56)(8)(4)(44)(44)(21)(5)(3)(1)(2)(6)(3)(23)(3)(2)(18)	0.001
 Table 4, Overview of Informed choice
*=Respondents answered 'yes' to the question: 'did you read the leaflet?' and spent 1 minute or more on reading the leaflet. 
**=Respondents answered ‘no' to the question: 'did you read the leaflet? or spent less than 1 minute on reading the leaflet.
*** = P-value is corrected for educational level. 
Percentages may not add to 100 because of rounding
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